Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.31 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL720728 | 1.00 | L3MBTL1 (0.38) | L3MBTL1KAT2BBAZ2BPIK3CDCYP19A1 | |
| Hydrochloric Acid SCHEMBL17005253 | 0.98 | L3MBTL1 (0.37) | L3MBTL1KAT2BBAZ2BPIK3CDCYP19A1 | |
| Hydrochloric Acid SCHEMBL17005254 | 0.98 | L3MBTL1 (0.37) | L3MBTL1KAT2BBAZ2BPIK3CDCYP19A1 | |
| SCHEMBL23819043 | 0.89 | CTSL (0.38) | L3MBTL1PIK3CDLMNAACACB | |
| SCHEMBL31461598 | 0.89 | CTSL (0.38) | L3MBTL1PIK3CDLMNAACACB | |
| SCHEMBL23819181 | 0.89 | CTSL (0.38) | L3MBTL1PIK3CDLMNAACACB | |
| Hydrochloric Acid SCHEMBL30338425 | 0.87 | CTSL (0.38) | L3MBTL1LMNAACACB | |
| SCHEMBL14095422 | 0.86 | CYP19A1 (0.39) | CYP19A1TSHRLMNACHRM2CHRM4 | |
| SCHEMBL19706447 | 0.86 | — | — | |
| SCHEMBL154764 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-115175735-B | Antiviral compounds | 吉利德科学公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-118598916-A | Antiviral compounds | 吉利德科学公司 | 2024-09-06 | — | — | CN | disclosed |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-29 | — | — | US | disclosed |
| CN-115135383-B | Antiviral compounds | 吉利德科学公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-11767337-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2023-09-21 | — | — | US | disclosed |
| EP-4172160-A2 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | MARQUIS DAVID M (US) | 2005-01-06 | — | — | US | disclosed |
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | VICTORIA EDWARD JESS (US) | 2004-01-15 | — | — | US | disclosed |
| US-6410775-B1 | HYDROPHILIC COUPLING | LA JOLLA PHARMACEUTICAL COMPANY | 2002-06-25 | — | — | US | disclosed |
| EP-1092027-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 BETA 2 GP1 POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (CA) | 2001-04-18 | — | — | EP | disclosed |
| WO-1999064595-A9 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | JOLLA PHARMA (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-1999064595-A1 | THERAPEUTIC AND DIAGNOSTIC DOMAIN 1 β2GPI POLYPEPTIDES AND METHODS OF USING SAME | LA JOLLA PHARMACEUTICAL COMPANY (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0954531-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | Lajolla Pharmaceutical Company (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0954531-A4 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1999-08-31 | — | — | EP | disclosed |
| WO-1997046251-A9 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | — | 1998-06-04 | — | — | WO | disclosed |
| WO-1997046251-A1 | aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES | LAJOLLA PHARMACEUTICAL COMPANY (US) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295201-A1 | ANTIVIRAL COMPOUNDS | MAVS, HAVCR2, ZC3HAV1 | L3MBTL1 2111/4885KAT2B 4093/4885BAZ2B 3212/4885 |
| US-20040009904-A1 | APL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies | CD4, VSIG8, PTMS | L3MBTL1 981/4885KAT2B 3375/4885BAZ2B 1498/4885 |
| US-11767337-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | L3MBTL1 2111/4885KAT2B 4093/4885BAZ2B 3212/4885 |
| US-20050004351-A1 | Therapeutic and diagnostic domain 1 beta2GP1 polypeptides and methods of using same | PLTP, PA2G4, PAG1 | L3MBTL1 188/4885KAT2B 4275/4885BAZ2B 4167/4885 |
| US-20240287109-A1 | 1'-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | TYMP, PNP, DUT | L3MBTL1 1094/4885KAT2B 3588/4885BAZ2B 3744/4885 |
| US-12404289-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | L3MBTL1 1076/4885KAT2B 3603/4885BAZ2B 3341/4885 |
| US-11939347-B2 | 1′-cyano nucleoside analogs and uses thereof | TYMP, PNP, DUT | L3MBTL1 1076/4885KAT2B 3603/4885BAZ2B 3341/4885 |
| US-20260035394-A1 | 1`-CYANO NUCLEOSIDE ANALOGS AND USES THEREOF | PNP, SLC28A1, SLC29A1 | L3MBTL1 2701/4885KAT2B 3329/4885BAZ2B 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.